700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Stavudine is an antiviral drug which is used in the control of HIV and tuberculosis therapy. There are considerable inter-individual variations in serum concentration of stavudine due to short half-life. In this study, stavudine was therefore selected as the model drug and effects of different polymers (Eudragit RSPO, Eudragit RLPO and Hydroxypropyl methylcellulose) in differing combinations and ratios were studied on swelling behavior of the tablets and release pattern of stavudine from the formulations. All tablets were acceptable with regard to thickness, weight variation, hardness, and drug content. The formulation (F7) having combination of Eudragit RSPO and Eudragit RLPO (1:2) and 10% hydroxypropyl methylcellulose showed 208.21 + 0.66 % swelling, 48.33 + 1.49 % erosion and 90.43 ± 1.11% drug release. Maximum release was observed by increasing the content of Eudragit RLPO. Optimized formulations were subjected to stability studies for six months which showed stability with regards to release pattern.
Stavudine, Eudragit, Hydoxypropyl Methylcellulose, Swelling, Erosion, In vitro release study